Mr. Dable joined Acceleron in December 2016 as the Company’s President and Chief Executive Officer and member of its Board of Directors.
Mr. Dable most recently served as President of U.S. Pharmaceuticals at Bayer AG. During his 22-year tenure there, Mr. Dable held positions of increasing responsibility. In addition to President of U.S. Pharmaceuticals, he also served as Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology, Global Launch Team Head, EYLEA®, Global Head, Neurology and Ophthalmology; Vice President, Regional Head, Hematology and Cardiology; Director of International Sales and Marketing, Biologics Research; and Head of Strategic Planning, Pharmaceuticals, Japan. Mr. Dable’s earlier experience at Bayer AG includes various sales and sales management positions in Canada.
As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. Mr. Dable also managed research and development collaborations and served on Joint Steering Committees with companies such as Algeta ASA, Orion Corporation and Regeneron Pharmaceuticals.
Mr. Dable is a former member of the Board of Directors of Millendo Therapeutics and recently served on the Board of Directors of the Biotechnology Innovation Organization (BIO).
Mr. Dable received a B.B.A. in Marketing and Finance and his M.B.A. from the University of New Brunswick.
What is Habib J. Dable's net worth?
The estimated net worth of Habib J. Dable is at least $15.38 million as of January 5th, 2021. Mr. Dable owns 86,046 shares of Acceleron Pharma stock worth more than $15,380,723 as of November 19th. This net worth approximation does not reflect any other assets that Mr. Dable may own. Learn More about Habib J. Dable's net worth.
How do I contact Habib J. Dable?
Has Habib J. Dable been buying or selling shares of Acceleron Pharma?
Habib J. Dable has not been actively trading shares of Acceleron Pharma during the past quarter. Most recently, Habib J. Dable sold 57,814 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $126.73, for a transaction totalling $7,326,768.22. Learn More on Habib J. Dable's trading history.
Who are Acceleron Pharma's active insiders?
